Efficacy and safety of two different treatment patterns of ranibizumab in patients with wet AMD

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-004959-39

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is to evaluate the effectiveness of two treatment regimens by assessing the average BCVA change from Month 4 to Month 12 compared to Month 3 based on both, BCVA stability in each treatment group and comparison of the two treatment groups. For the analysis of these objectives a reference margin of two letters will be applied. A treatment regimen will be considered a relevant option if stability is achieved and non-inferiority compared to the other group is demonstrated.


Critère d'inclusion

  • Visual impairment due to neovascular AMD